Bausch Health Companies Inc. agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800 percent price hike in 2015.
https://www.pharmalive.com/wp-content/uploads/2021/09/Bausch-to-pay-300-mln-in-antitrust-suit-over-diabetes-drug-Reuters-9-9-21.jpg503960Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-09-09 18:09:332021-09-09 23:48:23Bausch to pay $300 million in antitrust suit over diabetes drug